US · Healthcare

Relmada Therapeutics Inc (RLMD)

Biotechnology

Relmada Therapeutics Inc (RLMD) is listed on US in the Healthcare sector. Industry: Biotechnology. As of 2026-05-23, reported P/E ratio is 25.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Download on the App Store Get it on Google Play

Key metrics for RLMD

P/E ratio

25.00

Relmada Therapeutics Inc (RLMD) — FAQ

What is RLMD's P/E ratio?

The price-to-earnings (P/E) ratio for Relmada Therapeutics Inc (RLMD) is 25.00 (data as of 2026-05-23).

Does Relmada Therapeutics Inc pay a dividend?

Dividend yield is not available in the current snapshot for Relmada Therapeutics Inc (RLMD). Check the MyAverix Finance app for the latest dividend data.

What sector is Relmada Therapeutics Inc in?

Relmada Therapeutics Inc (RLMD) is classified in the Healthcare sector (Biotechnology industry).

What exchange is RLMD listed on?

RLMD is listed on US.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)